Bellicum Pharmaceuticals, Inc. – NASDAQ:BLCM

Financial Health
0
1
2
3
4
5
6
7
8
9

Bellicum Pharmaceuticals stock price monthly change

-20.00%
month

Bellicum Pharmaceuticals stock price quarterly change

-4.38%
quarter

Bellicum Pharmaceuticals stock price yearly change

-92.32%
year

Bellicum Pharmaceuticals key metrics

Market Cap
778.32K
Enterprise value
N/A
P/E
-0.38
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
1.66
Price/Book
0.82
PEG ratio
N/A
EPS
-1.58
Revenue
N/A
EBITDA
-25.33M
Income
-21.79M
Revenue Q/Q
N/A
Revenue Y/Y
0.53%
Profit margin
-1157.06%
Oper. margin
-1248.43%
Gross margin
0%
EBIT margin
-1248.43%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Bellicum Pharmaceuticals stock price history

Bellicum Pharmaceuticals stock forecast

Bellicum Pharmaceuticals financial statements

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM): Profit margin
Dec 2022 500K -6.19M -1239%
Mar 2023 8K -7.48M -93587.5%
Jun 2023 0 -7.35M
Sep 2023 1M -763K -76.3%
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM): Analyst Estimates
2025 6M -15.41M -256.9%
  • Analysts Price target

  • Financials & Ratios estimates

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM): Earnings per share (EPS)
2023-05-11 -0.19882 -0.26
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM): Debt to assets
Dec 2022 23823000 21.80M 91.54%
Mar 2023 17260000 27.28M 158.05%
Jun 2023 8733000 30.57M 350.09%
Sep 2023 6853000 33.86M 494.19%
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM): Cash Flow
Dec 2022 -6.91M -7K 0
Mar 2023 -6.43M -5K 0
Jun 2023 -7.99M 1K 0
Sep 2023 -1.51M 15K 0

Bellicum Pharmaceuticals alternative data

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM): Employee count
Aug 2023 13
Sep 2023 13
Oct 2023 13
Nov 2023 13
Dec 2023 13
Jan 2024 13
Feb 2024 13
Mar 2024 13
Apr 2024 13
May 2024 13
Jun 2024 13
Jul 2024 13

Bellicum Pharmaceuticals other data

15.10% +0.70%
of BLCM is owned by hedge funds
1.73M +269.16K
shares is hold by hedge funds

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM): Insider trades (number of shares)
Period Buy Sel
Aug 2019 28000 0
Sep 2019 40000 0
Mar 2020 5000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
STONEHOUSE JON P director Common Stock 121,452 N/A N/A
Option
HUBER REID M director
Common Stock 87,196 N/A N/A
Option
DAVIS STEPHEN director Common Stock 74,739 N/A N/A
Option
DALY JAMES M director
Common Stock 60,414 N/A N/A
Option
KLIMOVSKY JUDITH V director Common Stock 60,414 N/A N/A
Option
HUBER REID M director
Common Stock 80,968 N/A N/A
Option
STONEHOUSE JON P director Common Stock 60,580 N/A N/A
Option
HUBER REID M director
Common Stock 46,489 N/A N/A
Option
DALY JAMES M director
Common Stock 35,082 N/A N/A
Option
STONEHOUSE JON P director Common Stock 60,580 N/A N/A
Patent
Application
Filling date: 12 Aug 2020 Issue date: 1 Sep 2022
Application
Filling date: 21 Jun 2021 Issue date: 19 May 2022
Application
Filling date: 9 Jun 2021 Issue date: 28 Apr 2022
Application
Filling date: 12 Dec 2019 Issue date: 3 Mar 2022
Application
Filling date: 29 Oct 2019 Issue date: 6 Jan 2022
Application
Filling date: 7 Dec 2020 Issue date: 11 Nov 2021
Application
Filling date: 8 May 2018 Issue date: 20 May 2021
Application
Filling date: 6 May 2019 Issue date: 15 Apr 2021
Grant
Filling date: 13 Feb 2015 Issue date: 2 Mar 2021
Grant
Filling date: 11 Feb 2020 Issue date: 16 Feb 2021
  • When is Bellicum Pharmaceuticals's next earnings date?

    Unfortunately, Bellicum Pharmaceuticals's (BLCM) next earnings date is currently unknown.

  • Does Bellicum Pharmaceuticals pay dividends?

    No, Bellicum Pharmaceuticals does not pay dividends.

  • How much money does Bellicum Pharmaceuticals make?

    Bellicum Pharmaceuticals has a market capitalization of 778.32K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 75.81% to 1.5M US dollars. Bellicum Pharmaceuticals made a loss 24.97M US dollars in net income (profit) last year or -$0.26 on an earnings per share basis.

  • What is Bellicum Pharmaceuticals's stock symbol?

    Bellicum Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "BLCM".

  • What is Bellicum Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Bellicum Pharmaceuticals?

    Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Bellicum Pharmaceuticals's key executives?

    Bellicum Pharmaceuticals's management team includes the following people:

    • Mr. Richard A. Fair Pres, Chief Executive Officer & Director(age: 56, pay: $896,530)
  • How many employees does Bellicum Pharmaceuticals have?

    As Jul 2024, Bellicum Pharmaceuticals employs 13 workers.

  • When Bellicum Pharmaceuticals went public?

    Bellicum Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 18 Dec 2014.

  • What is Bellicum Pharmaceuticals's official website?

    The official website for Bellicum Pharmaceuticals is bellicum.com.

  • Where are Bellicum Pharmaceuticals's headquarters?

    Bellicum Pharmaceuticals is headquartered at 3730 Kirby Drive, Houston, TX.

  • How can i contact Bellicum Pharmaceuticals?

    Bellicum Pharmaceuticals's mailing address is 3730 Kirby Drive, Houston, TX and company can be reached via phone at 281 454 3424.

Bellicum Pharmaceuticals company profile:

Bellicum Pharmaceuticals, Inc.

bellicum.com
Exchange:

NASDAQ

Full time employees:

13

Industry:

Biotechnology

Sector:

Healthcare

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

3730 Kirby Drive
Houston, TX 77098

CIK: 0001358403
ISIN: US0794814048
CUSIP: 079481404